(1)
Owonikoko, T.; Papadopoulos, K.; Johnson, M.; al., et. Phase 1 Study of Cemiplimab, a Human Monoclonal Anti-PD-1 Antibody, in Patients With Unresectable Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC): Longer Follow-up Efficacy and Safety Data. J of Skin 2019, 3, 169.